Last reviewed · How we verify
AERAS-402 3 x 10^10 vp
AERAS-402 is a vaccine designed to stimulate an immune response against tuberculosis.
AERAS-402 is a vaccine designed to stimulate an immune response against tuberculosis. Used for Tuberculosis prevention.
At a glance
| Generic name | AERAS-402 3 x 10^10 vp |
|---|---|
| Also known as | AERAS-402 |
| Sponsor | Aeras |
| Drug class | vaccine |
| Target | TB10.4 antigen |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
AERAS-402 is a recombinant adenovirus vector-based vaccine that aims to induce cellular and humoral immunity against Mycobacterium tuberculosis. This vaccine has been engineered to express the TB10.4 antigen, which is a key component of the M. tuberculosis cell wall.
Approved indications
- Tuberculosis prevention
Common side effects
- Injection site pain
Key clinical trials
- Study of AERAS-402 in Healthy Infants (PHASE1, PHASE2)
- Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults (PHASE2)
- A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB (PHASE2)
- A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AERAS-402 3 x 10^10 vp CI brief — competitive landscape report
- AERAS-402 3 x 10^10 vp updates RSS · CI watch RSS
- Aeras portfolio CI